122 related articles for article (PubMed ID: 22174000)
21. Comparison of peripheral zone and central gland volume in patients undergoing intensity-modulated radiotherapy.
Zechmann CM; Simpfendörfer T; Giesel FL; Zamecnik P; Thieke C; Hielscher T; Meinzer HP; Delorme S
J Comput Assist Tomogr; 2010; 34(5):739-45. PubMed ID: 20861778
[TBL] [Abstract][Full Text] [Related]
22. Multiparametric magnetic resonance imaging of the prostate: current status in prostate cancer detection, localization, and staging.
Macura KJ
Semin Roentgenol; 2008 Oct; 43(4):303-13. PubMed ID: 18774034
[No Abstract] [Full Text] [Related]
23. PET/CT and radiotherapy in prostate cancer.
De Jong IJ; De Haan TD; Wiegman EM; Van Den Bergh AC; Pruim J; Breeuwsma AJ
Q J Nucl Med Mol Imaging; 2010 Oct; 54(5):543-52. PubMed ID: 20927021
[TBL] [Abstract][Full Text] [Related]
24. Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion.
Fonteyne V; Villeirs G; Speleers B; De Neve W; De Wagter C; Lumen N; De Meerleer G
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):799-807. PubMed ID: 18407430
[TBL] [Abstract][Full Text] [Related]
25. MRI and surveillance.
Ouzzane A; Puech P; Villers A
Curr Opin Urol; 2012 May; 22(3):231-6. PubMed ID: 22388665
[TBL] [Abstract][Full Text] [Related]
26. Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor--correlation with biopsy findings.
Rouvière O; Valette O; Grivolat S; Colin-Pangaud C; Bouvier R; Chapelon JY; Gelet A; Lyonnet D
Urology; 2004 May; 63(5):922-7. PubMed ID: 15134982
[TBL] [Abstract][Full Text] [Related]
27. [Magnetic resonance imaging in management of prostate cancer].
Boesen L; Thomsen HS
Ugeskr Laeger; 2013 Jun; 175(23):1630-3. PubMed ID: 23731989
[TBL] [Abstract][Full Text] [Related]
28. Prediction of locally recurrent prostate cancer after radiation therapy: incremental value of 3T diffusion-weighted MRI.
Kim CK; Park BK; Lee HM
J Magn Reson Imaging; 2009 Feb; 29(2):391-7. PubMed ID: 19161194
[TBL] [Abstract][Full Text] [Related]
29. Value of endorectal MRI and MRS in patients with elevated prostate-specific antigen levels and previous negative biopsies to localize peripheral zone tumours.
Cirillo S; Petracchini M; Della Monica P; Gallo T; Tartaglia V; Vestita E; Ferrando U; Regge D
Clin Radiol; 2008 Aug; 63(8):871-9. PubMed ID: 18625351
[TBL] [Abstract][Full Text] [Related]
30. Experience improves staging accuracy of endorectal magnetic resonance imaging in prostate cancer: what is the learning curve?
Latchamsetty KC; Borden LS; Porter CR; Lacrampe M; Vaughan M; Lin E; Conti N; Wright JL; Corman JM
Can J Urol; 2007 Feb; 14(1):3429-34. PubMed ID: 17324322
[TBL] [Abstract][Full Text] [Related]
31. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
[TBL] [Abstract][Full Text] [Related]
32. The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy.
Buyyounouski MK; Horwitz EM; Uzzo RG; Price RA; McNeeley SW; Azizi D; Hanlon AL; Milestone BN; Pollack A
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1383-91. PubMed ID: 15275723
[TBL] [Abstract][Full Text] [Related]
33. Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-dimensional pathologic mapping of the prostate--a 4-year experience.
Barzell WE; Melamed MR
Urology; 2007 Dec; 70(6 Suppl):27-35. PubMed ID: 18194708
[TBL] [Abstract][Full Text] [Related]
34. [Endorectal magnetic resonance imaging for staging of prostatic cancer].
Hayashi N; Kawamura J; Sugimura Y
Hinyokika Kiyo; 1996 Oct; 42(10):767-73. PubMed ID: 8951473
[TBL] [Abstract][Full Text] [Related]
35. Functional magnetic resonance imaging in prostate cancer.
Seitz M; Shukla-Dave A; Bjartell A; Touijer K; Sciarra A; Bastian PJ; Stief C; Hricak H; Graser A
Eur Urol; 2009 Apr; 55(4):801-14. PubMed ID: 19185981
[TBL] [Abstract][Full Text] [Related]
36. Application of dose compensation in image-guided radiotherapy of prostate cancer.
Wu Q; Liang J; Yan D
Phys Med Biol; 2006 Mar; 51(6):1405-19. PubMed ID: 16510952
[TBL] [Abstract][Full Text] [Related]
37. The magnetic resonance detected intraprostatic lesion in prostate cancer: planning and delivery of intensity-modulated radiotherapy.
De Meerleer G; Villeirs G; Bral S; Paelinck L; De Gersem W; Dekuyper P; De Neve W
Radiother Oncol; 2005 Jun; 75(3):325-33. PubMed ID: 15967524
[TBL] [Abstract][Full Text] [Related]
38. MRI of prostatic cancer: in vivo and in vitro MRI results compared with pathological findings.
Nishimura K; Hida S; Okada K; Yoshida O; Nishimura K
Hinyokika Kiyo; 1988 Aug; 34(8):1333-8. PubMed ID: 3195401
[TBL] [Abstract][Full Text] [Related]
39. Role of MRI in minimally invasive focal ablative therapy for prostate cancer.
Rosenkrantz AB; Scionti SM; Mendrinos S; Taneja SS
AJR Am J Roentgenol; 2011 Jul; 197(1):W90-6. PubMed ID: 21701001
[TBL] [Abstract][Full Text] [Related]
40. [Magnetic resonance imaging of prostate cancer].
Kenttämies A; Rannikko A
Duodecim; 2015; 131(13-14):1233-44. PubMed ID: 26536720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
